Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,821,975

« Back to Dashboard
Patent 6,821,975 protects ADCIRCA and CIALIS and is included in two NDAs. There have been zero Paragraph IV challenges on Adcirca and Cialis There are four tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has thirty-seven patent family members in thirty-two countries.

Summary for Patent: 6,821,975

Title: Beta-carboline drug products
Abstract:A compound of structural formula (I), and pharmaceutically acceptable salts and solvates thereof, wherein the compound is in free drug particulate form, is disclosed.
Inventor(s): Anderson; Neil R. (West Lafayette, IN), Hartauer; Kerry J. (Carmel, IN), Kral; Martha A. (Indianapolis, IN), Stephenson; Gregory A. (Fishers, IN)
Assignee: Lilly ICOS LLC (Wilmington, DE)
Application Number:10/031,463
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 4th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Eli Lilly Co
TABLET;ORAL022332-001May 22, 2009RXYes6,821,975► subscribeYY
TABLET;ORAL021368-004Jan 7, 2008RXNo6,821,975► subscribeYY TREATMENT OF SEXUAL DYSFUNCTION
TABLET;ORAL021368-004Jan 7, 2008RXNo6,821,975► subscribeYY ERECTILE DYSFUNCTION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,821,975

PCT Information
PCT FiledAugust 01, 2000PCT Application Number:PCT/US00/20981
PCT Publication Date:February 08, 2001PCT Publication Number: WO01/08688

International Patent Family for Patent: 6,821,975

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina033953► subscribe
Austria264680► subscribe
Australia6508400► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.